Skip to main content
Article thumbnail
Location of Repository

Piroxicam and intracavitary platinum-based chemotherapy for the treatment of advanced mesothelioma in pets: preliminary observations

By Enrico P Spugnini, Stefania Crispi, Alessandra Scarabello, Giovanni Caruso, Gennaro Citro and Alfonso Baldi


Malignant Mesothelioma is an uncommon and very aggressive tumor that accounts for 1% of all the deaths secondary to malignancy in humans. Interestingly, this neoplasm has been occasionally described in companion animals as well. Aim of this study was the preclinical evaluation of the combination of piroxicam with platinum-based intracavitary chemotherapy in pets. Three companion animals have been treated in a three years period with this combination. Diagnosis was obtained by ultrasonographic exam of the body cavities that evidenced thickening of the mesothelium. A surgical biopsy further substantiated the diagnosis. After drainage of the malignant effusion from the affected cavity, the patients received four cycles of intracavitary CDDP at the dose of 50 mg/m2 every three weeks if dogs or four cycles of intracavitary carboplatin at the dose of 180 mg/m2 (every 3 weeks) if cats, coupled with daily administration of piroxicam at the dose of 0.3 mg/kg. The therapy was able to arrest the effusion in all patients for variable remission times: one dog is still in remission after 3 years, one dog died of progressive disease after 8 months and one cat died due to progressive neoplastic growth after six months, when the patient developed a mesothelial cuirass. The combination showed remarkable efficacy at controlling the malignant effusion secondary to MM in our patients and warrants further investigations

Topics: Research
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2007). A: Cell cycle molecules in mesothelioma: an overview.
  2. (2006). A: Human malignant mesothelioma: Molecular mechanisms of pathogenesis and progression.
  3. (1997). A: The retinoblastoma gene family pRb/p105, p107, pRb2/p130 and simian virus-40 large T-antigen in human mesotheliomas. Nat Med
  4. (2005). Aaronson SA: Evidence against a role for SV40 in human mesothelioma. Cancer Res
  5. (1998). Chung A: Mechanisms in the pathogenesis of asbestosis and silicosis.
  6. (1999). E: The European mesothelioma epidemic.
  7. (1998). G: Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
  8. (2005). HI: SV40 detection in human tumor specimens. Cancer Res
  9. (1993). L: Randomized phase II trial of CDDP with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.
  10. (1987). LH: Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study.
  11. (2003). Manegold C: Chemotherapy for malignant pleural mesothelioma. Curr Opin Oncol
  12. (2005). RA: Malignant mesothelioma. The Lancet

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.